Zilucoplan

CCCCCCCCCCCCCCCC(N[C@H](C(O)=O)CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](NC([C@@H](NC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N(C([C@@H]2CC(NCCCC[C@H](NC(C)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=CC=C3)C(N2)=O)=O)=O)=O)=O)=O)=O)C)CC(O)=O)=O)C(C)(C)C)=O)CC4=CC=C(O)C=C4)=O)CC5=CNC6=C5C=CC=N6)=O)CCC(O)=O)=O)CC7=CC=C(O)C=C7)=O)=O)C8CCCCC8)=O)C(O)=O)=O)=O)=O

[1]Julien S, et, al. Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model. Biomedicines. 2022 Aug 20;10 (8) :2036.|[2]Gorman DM, et, al. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids. 2021 Jan;53 (1) :143-147.